West Clinic Researchers Present Findings at 2013 American Society for Clinical Oncology (ASCO) Meeting
MEMPHIS, Tenn., May 31, 2013 /PRNewswire-USNewswire/ -- The West Clinic, the Mid-South's premier cancer center and world-class center of excellence in medical oncology, hematology, oncologic imaging, clinical research and other advanced medical care, announced today five of its physician-researchers will participate in ten presentations at the 49th Annual American Society of Clinical Oncology (ASCO) Meeting to be held May 31-June 4, 2013 in Chicago, IL at the McCormick Palace. Over 30,000 members of the oncology community from across the nation and around the world are expected to attend the five-day international scientific and educational oncology conference. This year's theme is "Building Bridges to Conquer Cancer."
The West Clinic's findings, which focus on leading-edge treatments for non-small cell lung cancer, colorectal cancer, lymphoma, and breast cancer, were selected by a highly competitive peer-review process.
"The West Clinic continues to further its research mission with a strong showing at ASCO, the world's premier oncology meeting," according to Lee S. Schwartzberg, MD, FACP, Medical and Research Director, The West Clinic; President, ACORN Research, LLC; and Chief, Division of Hematology/Oncology and Professor of Medicine, University of Tennessee Health Science Center. "Over 5000 abstracts from around the world were submitted this year. Our invitation to present four out of five West Clinic/ACORN abstracts reflects our reputation for being a major oncology research center. We are also pleased that our Chief Fellow, Dr. Jessica Snider, is first author on an important neo-adjuvant breast cancer trial that she will present."
Landmark research has been a heritage of The West Clinic and its continued commitment to a robust program is strong with participation in approximately 40 open studies, 12 of which are Phase I. West Clinic physicians conduct a broad spectrum of clinical research trials ranging from Phase I to Phase IV studies in collaboration with major pharmaceutical companies, the National Cancer Institute, cooperative groups, and its own investigator initiated trials funded by grants. West Clinic has one of the most advanced research programs of its kind in the country and played a major role in the development of new drugs for breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, and many other diseases.
"This year's theme Building Bridges to Conquer Cancer parallels our vision and unique collaboration with the University of Tennessee Health Science Center, Methodist Healthcare, and researchers across the country through ACORN Research, further positioning West Clinic as an innovative leader, exploring new cancer-fighting treatments, and saving more lives," stated Dr. Schwartzberg.
The following West Clinic physicians contributed to ASCO presentations.
GENERAL POSTER PRESENTATIONS
- Dr. Lee Schwartzberg: Serum and tumor biomarkers to predict outcome in the eLung trial, a multicenter, randomized phase IIb study of standard platinum doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small cell lung cancer (NSCLC). http://abstracts2.asco.org/AbstView_132_110479.html
- Dr. Lee Schwartzberg; Dr. Obiageli Ogbata: Real-world symptom burden and early treatment discontinuation in first-line metastatic breast cancer (MBC). http://abstracts2.asco.org/AbstView_132_110594.html
- Dr. Lee Schwartzberg: From Bayesian modeling to genomic mapping: Biologic validity of predictive single nucleotide polymorphism networks for chemotherapy-related side effects. http://abstracts2.asco.org/AbstView_132_114956.html
- Dr. Lee Schwartzberg: Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer. http://abstracts2.asco.org/AbstView_132_110308.html
- Dr. Lee Schwartzberg: Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). http://abstracts2.asco.org/AbstView_132_116726.html
- Dr. Lee Schwartzberg: Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC). http://abstracts2.asco.org/AbstView_132_113096.html
- Dr. Lee Schwartzberg: Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer. http://abstracts2.asco.org/AbstView_132_115057.html
- Dr. Jessica Snider: Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC). http://abstracts2.asco.org/AbstView_132_117576.html
- Dr. Brad Somer: Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) ly2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). http://abstracts2.asco.org/AbstView_132_108714.html
- Dr. Daruka Mahadevan: Genetic and cytokine profiles associated with symptomatic stage of CLL. http://abstracts2.asco.org/AbstView_132_113916.html
PUBLICATIONS ONLY
- Dr. Lee Schwartzberg: A phase IIb trial of coix seed injection for advanced pancreatic cancer. http://abstracts2.asco.org/AbstView_132_115489.html
- Dr. Daruka Mahadevan: Phase Ib study of safety, tolerability, and efficacy of R1507 a monoclonal antibody to IGF-1R in combination with multiple standard chemotherapy regimens in patients with advanced solid malignancies. http://abstracts2.asco.org/AbstView_132_110601.html
WEST CLINIC EXPERTS AVAILABLE TO COMMENT ON LATEST ASCO REPORTS
West Clinic physicians will be available to comment on major ASCO reports throughout the meeting. For additional information, please contact Deborah Coble, Office: 901-683-0055 x 1312; cell: 901-831-1010 or [email protected].
About The West Clinic
The West Clinic has been the Mid-South's premier provider of cancer care for over 34 years. With a team second to none in breadth of expertise, dedication to excellence, and compassionate care, our multidisciplinary physician group is comprised of 34 specialists in Medical Oncology, Hematology, Gynecologic Oncology, Breast Surgery, Radiation Oncology, Endocrinology, Diagnostic and Interventional Radiology, Pain and Palliative Care, and other advanced medical care. With nine locations in Memphis, West TN, AR, and North MS, patients across the Mid-South have greater access to the highest quality care available. The West Clinic's clinical research program, under the direction of Lee S. Schwartzberg, MD, FACP, Medical Director, is internationally renowned. Over the past two decades, West Clinic has consistently been one of the first centers in the US to gain experience and hasten the development of new drugs for breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, and many other diseases. In 2012, The West Clinic formed a partnership with Methodist Healthcare and the University of Tennessee Health Science Center (UTHSC) in order to transform cancer care in the Mid-South. This novel partnership takes advantage of the strengths and culture of all three partners that are leading to the development of a fully integrated cancer program which will expand our collaborative efforts in cancer research and education along with a vision toward personalized precision cancer care. www.westclinic.com
CONTACT
Deborah Coble
Director, Corporate Communications
The West Clinic
901-683-0055 ext. 1312
[email protected]
SOURCE The West Clinic
Share this article